EPIDEMIOLOGICAL STUDY ON SMALL GESTATIONAL AGES

Image principale:

In the context of the Covid-19 epidemic, the French National Institute of Health and Medical Research (Inserm) has reached out to all individuals who have participated in epidemiologic studies in France, regardless of their age and sex, to complete a questionnaire about the Coronavirus (COVID-19) epidemic.

  •  The objectives of the survey

The objectives of this study in the general population are to:

-assess the incidence of symptoms of COVID-19,
-understand how the population is experiencing and adhering to these various public health measures, and
-learn how families are living and organizing during the lockdown.

  • Why are we asking the Epipage 2 families to participate?

We did NOT ask you to participate in this survey because we think that you or your children were at higher risk of being contaminated or developing serious cases. The scientific information currently available shows that the vast majority of children infected with COVID-19 do not have serious cases, which are extremely rare in this age group.

But we know that you, the parents of children in the Epipage cohort, are especially sensitive to the advancement of knowledge in different domains of health and hope that you might therefore be interested in this survey and in contributing to research in this area in France.

  •  Survey procedures

Parents of Epipage 2 children were invited to complete two questionnaires in April and May 2020.
The questionnaires focused on the child’s health related to Coronavirus, home schooling, changes in working life, family or individual safety and confinement measures or the behaviour of children in this potentially anxiety-causing situation.

A biological component of the survey also began in May, with some families taking serological samples to find out if they have been in contact with the Covid-19 virus.

  •  First results

40% of Epipage 2 children, almost 1,300 children, participated to this survey.
The first results were sent to you in the Epipage 2 newsletters of July 2020 and December 2020